NOVEN PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 610
- Market Cap
- -
- Website
- http://www.noven.com
Clinical Trials
6
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:2
Phase 2:2
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (33.3%)Phase 2
2 (33.3%)Phase 3
2 (33.3%)Irritation and Sensitization Study of HP-5000 Topical System
Phase 1
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: HP-5000 Topical PatchDrug: HP-5000 Placebo PatchDrug: Saline Patch
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04882319
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee
Phase 3
Completed
- Conditions
- Osteoarthritis Pain of the Knee
- Interventions
- Drug: Placebo patch
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 370
- Registration Number
- NCT04683627
- Locations
- 🇺🇸
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Clinical Research of West Florida,Inc., Clearwater, Florida, United States
🇺🇸Universal Axon Clinical Research, LLC, Doral, Florida, United States
Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch
Phase 1
- Conditions
- Cumulative Irritation and Sensitization
- Interventions
- Drug: HP-1050 Patch
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04624867
- Locations
- 🇺🇸
QPS Missouri, Springfield, Missouri, United States
A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
Phase 2
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT03277066
- Locations
- 🇺🇸
Noven Pharmaceuticals, Inc., Jersey City, New Jersey, United States
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Low Dose Asenapine maleate transdermal patchDrug: High Dose Asenapine maleate transdermal patchDrug: Placebo
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 617
- Registration Number
- NCT02876900
- Locations
- 🇺🇸
Noven Pharmaceuticals, Inc., Jersey City, New Jersey, United States
- Prev
- 1
- 2
- Next
News
No news found